Main Management ETF Advisors’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-792,750
| Closed | -$60.4M | – | 40 |
|
|
2023
Q1 | $60.4M | Buy |
792,750
+21,140
| +3% | +$1.61M | 5.13% | 10 |
|
|
2022
Q4 | $64M | Buy |
771,610
+295,865
| +62% | +$24.6M | 5.98% | 8 |
|
|
2022
Q3 | $37.7M | Buy |
475,745
+3,860
| +0.8% | +$306K | 4.33% | 11 |
|
|
2022
Q2 | $35M | Sell |
471,885
-965
| -0.2% | -$71.7K | 3.89% | 11 |
|
|
2022
Q1 | $42.5M | Buy |
472,850
+297,530
| +170% | +$26.7M | 3.95% | 11 |
|
|
2021
Q4 | $19.6M | Buy |
175,320
+9,000
| +5% | +$1.01M | 1.72% | 15 |
|
|
2021
Q3 | $20.9M | Buy |
166,320
+7,560
| +5% | +$950K | 2.11% | 15 |
|
|
2021
Q2 | $21.5M | Buy |
158,760
+8,280
| +6% | +$1.12M | 2.24% | 15 |
|
|
2021
Q1 | $20.4M | Sell |
150,480
-53,570
| -26% | -$7.27M | 2.41% | 15 |
|
|
2020
Q4 | $28.7M | Sell |
204,050
-550
| -0.3% | -$77.4K | 4.5% | 12 |
|
|
2020
Q3 | $22.8M | Sell |
204,600
-5,500
| -3% | -$613K | 4.02% | 11 |
|
|
2020
Q2 | $23.5M | Buy |
210,100
+9,350
| +5% | +$1.05M | 4.44% | 11 |
|
|
2020
Q1 | $15.5M | Sell |
200,750
-550
| -0.3% | -$42.6K | 3.72% | 10 |
|
|
2019
Q4 | $19.1M | Buy |
201,300
+8,800
| +5% | +$837K | 3.71% | 11 |
|
|
2019
Q3 | $14.7M | Sell |
192,500
-107,200
| -36% | -$8.17M | 3.19% | 11 |
|
|
2019
Q2 | $26.3M | Buy |
299,700
+18,000
| +6% | +$1.58M | 6.06% | 7 |
|
|
2019
Q1 | $25.5M | Buy |
281,700
+15,300
| +6% | +$1.39M | 5.92% | 7 |
|
|
2018
Q4 | $19.1M | Buy |
266,400
+15,300
| +6% | +$1.1M | 5.34% | 7 |
|
|
2018
Q3 | $24.1M | Buy |
251,100
+29,700
| +13% | +$2.85M | 6.06% | 7 |
|
|
2018
Q2 | $21.1M | Buy |
221,400
+33,300
| +18% | +$3.17M | 6.27% | 7 |
|
|
2018
Q1 | $16.5M | Buy |
188,100
+30,600
| +19% | +$2.68M | 5.85% | 7 |
|
|
2017
Q4 | $13.4M | Buy |
+157,500
| New | +$13.4M | 5.72% | 7 |
|